References
- 1. F. Wu, S. Zhao, B. Yu, Y.-M. Chen, W. Wang, Z.-G. Song, Y. Hu, Z.-W. Tao, J.-H. Tian, Y.-Y. Pei, M.-L. Yuan, Y.-L. Zhang, F.-H. Dai, Y. Liu, Q.-M. Wang, J.-J. Zheng, L. Xu, E. C. Holmes and Y.-Z. Zhang, A new coronavirus associated with human respiratory disease in China, Nature 579 (2020) 265–269; https://doi.org/10.1038/s41586-020-2008-310.1038/s41586-020-2008-3709494332015508
- 2. J. Xu, S. Zhao, T. Teng, A. E. Abdalla, W. Zhu, L. Xie, Y. Wang and X. Guo, Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV, Viruses 12 (2020) Article ID 244; https://doi.org/10.3390/v1202024410.3390/v12020244707719132098422
- 3. Z. Wang, X. Chen, Y. Lu, F. Chen and W. Zhang, Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment, Biosci. Trends 14 (2020) 64–68; https://doi.org/10.5582/bst.2020.0103010.5582/bst.2020.0103032037389
- 4. J. Lim, S. Jeon, H. Y. Shin, M. J. Kim, Y. M. Seong, W. J. Lee, K. W. Choe, Y. M. Kang, B. Lee and S. J. Park, Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR, J. Korean Med. Sci. 35 (2020) e79; https://doi.org/10.3346/jkms.2020.35.e7910.3346/jkms.2020.35.e79702591032056407
- 5. C. M. Chu, V. C. Cheng, I. F. Hung, M. M. Wong, K. H. Chan, K. S. Chan, R. Y. Kao, L. L. Poon, C. L. Wong, Y. Guan, J. S. Peiris and K. Y. Yuen, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax 59 (2004) 252–256; https://doi.org/10.1136/thorax.2003.01265810.1136/thorax.2003.012658174698014985565
- 6. S. J. Hurwitz and R. F. Schinazi, Practical considerations for developing nucleoside reverse transcriptase inhibitors, Drug Discov. Today Technol. 9 (2012) e183–e193; https://doi.org/10.1016/j.ddtec.2012.09.00310.1016/j.ddtec.2012.09.003361202523554824
- 7. N. Atatreh, S. Hasan, B. R. Ali and M. A. Ghattas, Computer-aided approaches reveal trihydroxychroman and pyrazolone derivatives as potential inhibitors of SARS-CoV-2 virus main protease, Acta Pharm. 71 (2021) 325–333; https://doi.org/10.2478/acph-2021-004010.2478/acph-2021-0040
- 8. Z. Lv, Y. Chu and Y. Wang, HIV protease inhibitors: a review of molecular selectivity and toxicity, HIV/AIDS (Auckland) 7 (2015) 95–104; https://doi.org/10.2147/HIV.S7995610.2147/HIV.S79956439658225897264
- 9. Y. Wang, J. Xiao, T. O. Suzek, J. Zhang, J. Wang, Z. Zhou, L. Han, K. Karapetyan, S. Dracheva, B. A. Shoemaker, E. Bolton, A. Gindulyte and S. H. Bryant, PubChem’s BioAssay Database, Nucleic Acids Res. 40 (2012) D400-D412; https://doi.org/10.1093/nar/gkr113210.1093/nar/gkr1132324505622140110
- 10. N. M. O’Boyle, M. Banck, C. A. James, C. Morley, T. Vandermeersch and G. R. Hutchison, Open Babel: An open chemical toolbox, J. Cheminform. 3 (2011) Article ID 33; https://doi.org/10.1186/1758-2946-3-3310.1186/1758-2946-3-33319895021982300
- 11. O. Trott and A. J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem. 31 (2010) 455–461; https://doi.org/10.1002/jcc.2133410.1002/jcc.21334304164119499576
- 12. R. A. Laskowski and M. B. Swindells, LigPlot+: multiple ligand-protein interaction diagrams for drug discovery, J. Chem. Inf. Model. 51 (2011) 2778–2786; https://doi.org/10.1021/ci200227u10.1021/ci200227u21919503
- 13. M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Z. Shi, Z. Hu, W. Zhong and G. Xiao, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res. 30 (2020) 269–271; https://doi.org/10.1038/s41422-020-0282-010.1038/s41422-020-0282-0705440832020029
- 14. S. Daoud, S. J. Alabed, L. A. Dahabiyeh, Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies, Acta Pharm. 71 (2021) 163–174; https://doi.org/10.2478/acph-2021-001610.2478/acph-2021-001633151166
- 15. T. P. Sheahan, A. C. Sims, S. R. Leist, A. Schäfer, J. Won, A. J. Brown, S. A. Montgomery, A. Hogg, D. Babusis, M. O. Clarke, J. E. Spahn, L. Bauer, S. Sellers, D. Porter, J. Y. Feng, T. Cihlar, R. Jordan, M. R. Denison and R. S. Baric, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat. Commun. 11 (2020) Article ID 222; https://doi.org/10.1038/s41467-019-13940-610.1038/s41467-019-13940-6695430231924756
- 16. A. H. de Wilde, D. Jochmans, C. C. Posthuma, J. C. Zevenhoven-Dobbe, S. van Nieuwkoop, T. M. Bestebroer, B. G. van den Hoogen, J. Neyts and E. J. Snijder, Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture, Antimicrob. Agents Chemother. 58 (2014) 4875–4884; https://doi.org/10.1128/AAC.03011-1410.1128/AAC.03011-14413607124841269
- 17. E. C. Vatansever, K. S. Yang, K. Kratch, A. Drelich, C.-C. Cho, D. M. Mellot, S. Xu, C.-T. K. Tseng and W. R. Liu, Targeting the SARS-CoV-2 main protease to repurpose drugs for COVID-19, bioRxiv preprint [Internet], posted May 23, 2020; https://doi.org/10.1101/2020.05.23.11223510.1101/2020.05.23.112235726349832511370
- 18. B. R. Beck, B. Shin, Y. Choi, S. Park and K. Kang, Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model, Comput. Struct. Biotechnol. J. 18 (2020) 784–790; https://doi.org/10.1016/j.csbj.2020.03.02510.1016/j.csbj.2020.03.025711854132280433
- 19. M. A. M. Subbaiah, S. Mandlekar, S. Desikan, T. Ramar, L. Subramani, M. Annadurai, S. D. Desai, S. Sinha, S. M. Jenkins and M. R. Krystal, Design, synthesis, and pharmacokinetic evaluation of phosphate and amino acid ester prodrugs for improving the oral bioavailability of the HIV-1 protease inhibitor atazanavir, J. Med. Chem. 62 (2019) 3553–3574; https://doi.org/10.1021/acs.jmedchem.9b0000210.1021/acs.jmedchem.9b0000230938524
- 20. M. Rittweger and K. Arastéh, Clinical pharmacokinetics of darunavir, Clin. Pharmacokin. 46 (2007) 739–756; https://doi.org/10.2165/00003088-200746090-0000210.2165/00003088-200746090-0000217713972
- 21. M. Mahdi, J. A. Mótyán, Z. I. Szojka, M. Golda, M. Miczi and J. Tőzsér, Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2’s main protease, Virol. J. 17 (2020) Article ID 190; https://doi.org/10.1186/s12985-020-01457-010.1186/s12985-020-01457-0768964033243253
- 22. S. Jo, S. Kim and D. H. Shin, Inhibition of SARS-CoV 3CL protease by flavonoids, J. Enzyme Inhib. Med. Chem. 35 (2020) 145–151; https://doi.org/10.1080/14756366.2019.169048010.1080/14756366.2019.1690480688243431724441
- 23. L. Zhang, D. Lin, Y. Kusov, Y. Nian, Q. Ma, J. Wang, A. von Brunn, P. Leyssen, K. Lanko, J. Neyts, A. de Wilde, E. J. Snijder and H. Liu, α-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment, J. Med. Chem. 63 (2020) 4562–4578; https://doi.org/10.1021/acs.jmedchem.9b0182810.1021/acs.jmedchem.9b01828709807032045235
- 24. M. M. Ghahremanpour, J. Tirado-Rives, M. Deshmukh, J. A. Ippolito, C.-H. Zhang, I. Cabeza de Vaca, M.-E. Liosi, K. S. Anderson and W. L. Jorgensen, Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2, ACS Med. Chem. Lett. 11 (2020) 2526–2533; https://doi.org/10.1021/acsmedchemlett.0c0052110.1021/acsmedchemlett.0c00521760532833324471